|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Pfizer (PFE: NYSE) By Morgan Stanley ($35.45, Sept. 20) We are upgrading Pfizer stock from Equal-weight to Overweight and raising our price target from $35 to $39. This is a multiple call. Following underperformance, ...
Pfizer's (PFE) key products contributing to growth include Eliquis, Ibrance, Lyrica, Xalkori, Xeljanz, and Xtandi.
Pfizer (PFE) filed a lawsuit in a U.S. district court alleging that J&J is resorting to anticompetitive practices to prevent uptake of Inflectra.